Meeting
2015 Gastrointestinal Cancers Symposium
Evolution of phase 1 trials for patients with advanced pancreatic cancer: An update on the experience from MD Anderson Cancer Center.
Authors
Jennifer Brooke Goldstein
The University of Texas MD Anderson Cancer Center, Houston, TX
Jennifer Brooke Goldstein , Chad Tang , David S. Hong , Vivek Subbiah , Filip Janku , Kenneth R. Hess , Siqing Fu , Daniel D. Karp , Aung Naing , Apostolia Maria Tsimberidou , Jennifer J. Wheler , Ralph Zinner , Milind M. Javle , Gauri R. Varadhachary , Robert A. Wolff , David R. Fogelman , Funda Meric-Bernstam , Sarina Anne Piha-Paul
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 320)
DOI
10.1200/jco.2015.33.3_suppl.320
Abstract #
320
Poster Bd #
B41
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104).
First Author: Stefan Boeck
Poster
2014 Gastrointestinal Cancers Symposium
The biomarkers of gemcitabine and erlotinib treatment in advanced pancreatic cancer.
First Author: Kuniyasu Irie
Poster
2014 Gastrointestinal Cancers Symposium
A phase 1 trial of GSL (gemcitabine, S-1, LV) combination therapy in advanced pancreatic cancer.
First Author: Yousuke Nakai
Poster
2013 ASCO Annual Meeting
Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC).
First Author: Dirk Strumberg